Ascendis Pharma AS (ASND) is a Healthcare · Biotechnology company listed on NASDAQ. Price $237.23 (-0.76%), Market cap $15.21B, P/E ratio 28.05, 52-week low–high $157.27 ~ $249.84.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Financial statements, price targets, institutional (13F) holdings and related news for Ascendis Pharma AS are updated in real time on BlackAll Trade.
Ascendis Pharma AS trades at $237.23 (-0.76%). Real-time quotes and charts are available on BlackAll Trade.
Ascendis Pharma AS has a market cap of about $15.21B. Its P/E ratio is 28.05.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company